SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Clinical trials for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS trials appear
Sign up with your email to follow new studies for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug aims to tame dangerous hormone in dialysis patients
Disease control CompletedThis study tested a drug called MT1013 for people on kidney dialysis who develop a bone-weakening condition called secondary hyperparathyroidism. Researchers gave 98 dialysis patients different doses of the drug or a placebo to check safety and see if it could lower a harmful hor…
Matched conditions: SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Phase: PHASE2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New injection tested to tame dangerous hormone in dialysis patients
Disease control CompletedThis study tested whether an experimental injection called MT1013 could safely and effectively lower high parathyroid hormone levels in people with advanced kidney disease who are on regular dialysis. The trial involved 115 participants and compared MT1013 against both an existin…
Matched conditions: SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Phase: PHASE2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC